A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.
Development of effective and immunogenic vaccines against highly pathogenic avian influenza H5N1 viruses with the potential to cause a pandemic is a public health priority. The global demand for a vaccine cannot be met in the event of an influenza pandemic because of the limited capacity to manufacture egg-derived vaccines as well as potential problems with the availability of embryonated eggs. Thus, there is an urgent need to develop alternative, egg-independent vaccines. We developed an adenoviral vector-based vaccine that contains hemagglutinin protein from clade 1 and clade 2 viruses, as well as conserved nucleoprotein, to broaden the vaccine coverage against H5N1 viruses.
Hoelscher
Mary A
MA
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Singh
Neetu
N
Garg
Sanjay
S
Jayashankar
Lakshmi
L
Veguilla
Vic
V
Pandey
Aseem
A
Matsuoka
Yumi
Y
Katz
Jacqueline M
JM
Donis
Ruben
R
Mittal
Suresh K
SK
Sambhara
Suryaprakash
S
D000256:Adenoviridae / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D006388:Hemagglutinins / Q000235:genetics / Q000276:immunology; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008168:Lung / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D009698:Nucleoproteins / Q000235:genetics / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology
D000914:Antibodies, Viral; D006388:Hemagglutinins; D007252:Influenza Vaccines; D009698:Nucleoproteins; D014614:Vaccines, Synthetic